Results The study selection process is outlined in figure 1
There's type one diabetes where the person is not able to produce insulin, and then there's type two diabetes where the person has insulin resistance, and so they need a higher level of insulin to achieve the effect
They may be able to provide alternative options or solutions
High fiber, polyphenols, consistent meal timing, reduced sugar, circadian alignment, SCFA-supportive synbiotics, and mucosal-restoring species like Akkermansia
Figure 1 The present review aims to elucidate and describe the molecular mechanisms of the GLP-1RA drugs, semaglutide and liraglutide, and their effectiveness and potential as a therapeutic option against obesity
Each participant began at 10:00 a.m